Clinical Trial: Phase III Clinical Study of Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease

U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT06879782) titled 'Phase III Clinical Study of Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease' on March 10.

Brief Summary: This study is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial designed to evaluate the efficacy and safety of Lifitegrast Ophthalmic Solution.

Study Start Date: March 28, 2024

Study Type: INTERVENTIONAL

Condition: Dry Eye Disease (DED)

Intervention: DRUG: Drug placebo

Instill one drop of the eye solution in each eye, twice a day (morning and evening, approximately 12 hours apart), for a treatment period of 12 weeks.

Recruitment Status: RECRUITING

Sponsor: Lunan B...